Eisenmenger Syndrome Treatment Market Will Exhibit an Impressive Expansion by 2024-2031

The global eisenmenger syndrome treatment market is anticipated to grow at a CAGR during the forecast period. The triad of systemic-to-pulmonary congenital cardiovascular communication, pulmonary arterial disease, and cyanosis is called Eisenmenger syndrome. The major factor that drives the market is consistent regulatory approval to the key players operating in the global market for the treatment of Eisenmenger syndrome by providing drugs, and therapy is expected to drive the market growth. For instance-

July 2021- The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US Food and Drug Administration (FDA) has approved UPTRAVI (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension in adult patients with WHO functional class (FC) II-III, who are temporarily unable to take oral therapy. UPTRAVI IV is a therapeutic option that will allow patients to avoid short-term treatment interruptions and stay on UPTRAVI therapy, as uninterrupted treatment is considered key for individuals with PAH.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/eisenmenger-syndrome-treatment-market

April 2021- The US FDA has granted a second approval to treprostinil (Tyvaso) inhalation solution, for the patines. Tyvaso DPI is the only therapy approved by the FDA for PH-ILD, when the blood pressure in the lungs is high due to a disease that causes lung scarring. Moreover, the convenience and portability of Tyvaso DPI make it an important new option for patients with WHO Group 1 PAH and with WHO Group 3 PH-ILD, with the potential for improving the quality of life for this patient population.

Global Eisenmenger Syndrome Treatment Market- Segmentation

By Drug Type

• Antiarrhythmic Agents
• Blood Thinning Agents
• Endothelin Receptor Antagonist
• Others

By Diagnosis

• Blood tests
• Electrocardiogram (ECG)
• Chest X-ray
• Echocardiogram
• Computerized tomography (CT) scan
• Magnetic resonance imaging (MRI)
• Cardiac catheterization

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

A full report of Eisenmenger Syndrome Treatment Market is available at: https://www.omrglobal.com/industry-reports/eisenmenger-syndrome-treatment-market

Eisenmenger Syndrome Treatment Market- Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Eli Lilly and Co.
• Gilead Sciences, Inc.
• GlaxoSmithKline
• Hikma Pharmaceuticals PLC
• Lupin Ltd.
• Merck & Co., Inc.
• Natco Pharma Ltd.
• Sun Pharma
• Viatris Inc
• Zydus Pharmaceuticals (USA) Inc.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.


Visit more report at

https://www.linkedin.com/pulse/scaffold-technology-market-size-trends-latest-arti-vishwakarma-mlsof/

https://www.linkedin.com/pulse/aesthetic-threads-market-increasing-demand-growth-2031-vishwakarma-pyg5f

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.